Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNGX
stocks logo

SNGX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.270
-76.32%
--
--
-0.460
-56.6%
--
--
-0.280
-65.85%
Estimates Revision
The market is revising No Change the revenue expectations for Soligenix, Inc. (SNGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -43.01%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-28.81%
In Past 3 Month
Stock Price
Go Down
down Image
-43.01%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Soligenix Inc (SNGX.O) is -1.45, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Soligenix Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.89
Current PE
-1.45
Overvalued PE
-0.26
Undervalued PE
-3.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
19.33
Current PS
0.00
Overvalued PS
35.78
Undervalued PS
2.88
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SNGX News & Events

Events Timeline

(ET)
2025-11-19
07:33:12
Soligenix finishes patient enrollment for Phase 3 trial assessing HyBryte
select
2025-10-07 (ET)
2025-10-07
07:33:58
Soligenix's HyBryte Reaches Safety Milestone in Phase 3 Trial for T-Cell Lymphoma
select
2025-09-30 (ET)
2025-09-30
07:32:22
Soligenix Enhances European Medical Advisory Board for CTCL
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-19Newsfilter
Soligenix Reaches Enrollment Target for Interim Analysis in Phase 3 Clinical Trial of HyBryte™ for Cutaneous T-Cell Lymphoma Treatment

  • Study Enrollment and Interim Analysis: Soligenix, Inc. has completed the enrollment of 50 patients in its Phase 3 FLASH 2 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL), with an interim analysis expected in Q2 2026. The study aims to confirm the efficacy of HyBryte™, building on previous successful trials.

  • Response Rates and Safety Profile: The overall blinded study response rate to date is 48%, significantly exceeding the anticipated 25%. The safety profile of HyBryte™ remains benign, consistent with earlier studies, and is expected to demonstrate efficacy over an extended treatment period.

  • Mechanism of Action and Treatment Approach: HyBryte™ utilizes synthetic hypericin activated by visible light, offering a safer alternative to traditional therapies that carry risks of DNA damage and secondary malignancies. This treatment approach targets malignant T-cells while minimizing systemic absorption.

  • Regulatory Path and Future Prospects: Following the first Phase 3 study, regulatory bodies require a second successful trial for marketing approval. Soligenix is in discussions with the FDA regarding study design modifications, while also pursuing additional studies to support HyBryte™'s efficacy and safety in treating CTCL.

[object Object]
Preview
9.5
11-07PRnewswire
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

  • Company Overview: Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, with key products including HyBryte™ for cutaneous T-cell lymphoma and SGX302 for psoriasis.

  • Recent Accomplishments: The company reported no safety concerns from the first Data Monitoring Committee meeting for HyBryte™ and announced updates to its Medical Advisory Boards in the U.S. and Europe to guide clinical development.

  • Financial Results: For the quarter ending September 30, 2025, Soligenix reported a net loss of $2.5 million, with approximately $10.5 million in cash, indicating a sufficient operating runway through 2026.

  • Future Outlook: The company is focused on upcoming milestones, including top-line results from clinical trials and exploring strategic options for funding and partnerships to advance its late-stage pipeline.

[object Object]
Preview
9.0
10-07Newsfilter
Soligenix Reaches Key Safety Milestone in Phase 3 Clinical Trial of HyBryte™ for Treating Cutaneous T-Cell Lymphoma

  • Study Progress: Soligenix, Inc. announced that the Data Monitoring Committee for its Phase 3 study of HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) found no safety concerns, with an interim efficacy analysis planned for 1H2026 and an enrollment update expected in 4Q2025.

  • Treatment Efficacy: HyBryte™ has shown promising efficacy and safety in previous studies, with a significant treatment response observed in patients with early-stage CTCL, offering a potential new option for patients with limited treatment alternatives.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Soligenix Inc (SNGX) stock price today?

The current price of SNGX is 1.63 USD — it has increased 5.16 % in the last trading day.

arrow icon

What is Soligenix Inc (SNGX)'s business?

Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

arrow icon

What is the price predicton of SNGX Stock?

Wall Street analysts forecast SNGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNGX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Soligenix Inc (SNGX)'s revenue for the last quarter?

Soligenix Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Soligenix Inc (SNGX)'s earnings per share (EPS) for the last quarter?

Soligenix Inc. EPS for the last quarter amounts to -0.58 USD, decreased -25.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for Soligenix Inc (SNGX)'s fundamentals?

The market is revising No Change the revenue expectations for Soligenix, Inc. (SNGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -43.01%.
arrow icon

How many employees does Soligenix Inc (SNGX). have?

Soligenix Inc (SNGX) has 14 emplpoyees as of December 05 2025.

arrow icon

What is Soligenix Inc (SNGX) market cap?

Today SNGX has the market capitalization of 16.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free